TrialDiabetologia2014

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.

David Polidori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.